- Syngene International announces a new protein production platform, aiming to improve efficiency and precision in preclinical and clinical development.
Syngene International Ltd., a global CRDMO, has unveiled its latest innovation in biopharmaceutical development: a new protein production platform. Developed in collaboration with Swiss biotech services company ExcellGene, the platform employs a cell line and transposon-based technology, promising to enhance the efficiency and precision of protein production.
The introduction of this platform is set to accelerate the development process, from preclinical stages to product launches, effectively reducing the time required to bring products to market. “This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process,” stated Sridevi Khambhampaty, Vice President, Biopharmaceutical Development at Syngene.
The collaboration between Syngene and ExcellGene is a strategic move to bolster biologics, which Syngene views as a pivotal element for future growth. “By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market,” commented Alex Del Priore, Senior Vice President, Manufacturing Services at Syngene.
The platform supports a diverse array of biomolecules, including monoclonal antibodies, biosimilars, and other recombinant proteins, and is compatible with both perfusion and fed-batch manufacturing processes. Syngene’s track record with this technology demonstrates its potential to revolutionize the company’s cell line development capabilities.
Overview of outsourcing trends 
